Real-world comparison of effectiveness between ustekinumab and a second-line anti-TNF agent in patients with symptomatic stricturing Crohn's disease failing to respond to a first-line anti-TNF agent: the USTEKNOSIS study.

ABSTRACT:

Background

Anti-tumor necrosis factor (TNF) agents are now accepted as the first-line medical treatment for stricturing Crohn's disease (CD). However, data are lacking about the effectiveness of advanced therapies after anti-TNF failure.

Objectives

To compare the effectiveness of ustekinumab and a second-line anti-TNF agent after failing to respond to a first-line anti-TNF for a symptomatic stricturing CD.

Design

Multicenter retrospective study.

Methods

We included consecutive adult patients with CD treated with ustekinumab or anti-TNF for symptomatic stricture (confirmed on imaging or endoscopy) after prior failure of one anti-TNF for the current stricture. Short-term endpoints were symptomatic remission (composite endpoint) at 6 months, defined as no abdomina

SUBMITTER: Le Cosquer G 

PROVIDER: S-EPMC12579123 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature